Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Terns Pharmaceuticals, Inc. - Common Stock (NQ: TERN )

5.860 -0.190 (-3.14%)
Streaming Delayed Price Updated: 4:00 PM EST, Dec 20, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 4,750,012
Open 5.900
Bid (Size) 5.800 (7)
Ask (Size) 6.000 (11)
Prev. Close 6.050
Today's Range 5.785 - 6.130
52wk Range 4.320 - 11.40
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Terns Pharmaceuticals Announces Positive Early Data from Phase 1 CARDINAL Trial of TERN-701 for Chronic Myeloid Leukemia
From Terns Pharmaceuticals, Inc.
Via GlobeNewswire
Terns Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(C)(4)
From Terns Pharmaceuticals, Inc.
Via GlobeNewswire

Performance

YTD
-9.57%
-9.57%
1 Month
+4.64%
+4.64%
3 Month
-41.52%
-41.52%
6 Month
-18.95%
-18.95%
1 Year
-7.57%
-7.57%

More News

Read More
Top 3 Health Care Stocks You'll Regret Missing In Q4
Via Benzinga
Terns Pharmaceuticals Appoints Heather Turner, J.D., to Board of Directors
From Terns Pharmaceuticals, Inc.
Via GlobeNewswire
Top 2 Health Care Stocks That May Collapse This Quarter
Via Benzinga
Terns Pharmaceuticals Reports Third Quarter 2024 Financial Results and Corporate Updates
From Terns Pharmaceuticals, Inc.
Via GlobeNewswire
Terns Pharmaceuticals to Participate in Upcoming November Investor Conferences
From Terns Pharmaceuticals, Inc.
Via GlobeNewswire
This Alumis Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday
Via Benzinga
Terns Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(C)(4)
From Terns Pharmaceuticals, Inc.
Via GlobeNewswire
As Weight-Loss Drugs Battle, Upstart Viking Therapeutics Threatens Eli Lilly, Novo Nordisk, Pfizer
Via Investor's Business Daily
This Small-Cap Stock Has a Promising GLP-1 Drug Which Could Rival Novo Nordisk and Eli Lilly's Weight-Loss Treatments
Via The Motley Fool
Applied Therapeutics, PowerFleet, VF Corp, Victoria's Secret And Other Big Stocks Moving Higher On Wednesday
Via Benzinga
Missed Out on Viking Therapeutics? Buy This Weight Loss Biotech Stock Right Now.
Via The Motley Fool
Should You Invest in This Under-the-Radar Weight Loss Stock?
Via The Motley Fool
1 New Weight Loss Drug Stock to Buy Now With $1,000 and Hold for 5 Years or More
Via The Motley Fool
Terns Announces Closing of Public Offering of Shares of Common Stock and Pre-Funded Warrants, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
From Terns Pharmaceuticals, Inc.
Via GlobeNewswire
Terns Announces Pricing of Upsized $150.15 Million Public Offering
From Terns Pharmaceuticals, Inc.
Via GlobeNewswire
Calavo Growers Posts Better-Than-Expected Earnings, Joins Tesla, Oracle, Mission Produce And Other Big Stocks Moving Higher On Tuesday
Via Benzinga
Oracle To Rally Around 29%? Here Are 10 Top Analyst Forecasts For Tuesday
Via Benzinga
Terns Announces Proposed Public Offering
From Terns Pharmaceuticals, Inc.
Via GlobeNewswire
Terns Pharmaceuticals, Boeing, Tesla And Other Big Stocks Moving Higher On Monday
Via Benzinga
Terns Pharmaceuticals' Oral GLP-1 Reaches Phase 1 Finish Line With Encouraging Weight Loss Data After One Month
Via Benzinga
Terns Pharmaceuticals Announces Positive Phase 1 Clinical Trial Results with TERN-601 Once-Daily Oral GLP-1R Agonist for the Treatment of Obesity
From Terns Pharmaceuticals, Inc.
Via GlobeNewswire
The 9 Pharma Stocks To Watch — Including Viking, Roche And Amgen — Amid The Fast-Growing Obesity Drug Race
Via Investor's Business Daily
TERN Stock Earnings: Terns Pharma Beats EPS for Q2 2024
Via InvestorPlace
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.